OncoMatch/Clinical Trials/NCT05914545
A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Is NCT05914545 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies FZ-AD004 for advanced and metastatic solid tumor.
Treatment: FZ-AD004 — This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify